Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Orexigen Therapeutic (OREX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 38,227
  • Shares Outstanding, K 15,230
  • Annual Sales, $ 33,710 K
  • Annual Income, $ -24,520 K
  • 36-Month Beta 2.45
  • Price/Sales 1.15
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +13.57%
on 07/19/17
3.10 -19.03%
on 06/28/17
-0.57 (-18.51%)
since 06/27/17
3-Month
2.21 +13.57%
on 07/19/17
3.64 -31.04%
on 05/09/17
-1.10 (-30.47%)
since 04/27/17
52-Week
1.65 +52.12%
on 12/14/16
5.70 -55.96%
on 02/10/17
-0.99 (-28.29%)
since 07/27/16

Most Recent Stories

More News
Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that its wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., and Biologix FZCO have amended the commercialization and distributorship...

OREX : 2.51 (-1.18%)
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017

Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the second quarter 2017 on Tuesday, August 8th after the market closes. Following the announcement, Orexigen...

OREX : 2.51 (-1.18%)
Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction

Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Company will present oral and poster presentations on OREX-1019 and OREX-1038 at the International Narcotics Research Conference (INRC)...

OREX : 2.51 (-1.18%)
Pricing, Competition Remain Headwinds for Pharma in 2017

Pricing, Competition Remain Headwinds for Pharma in 2017

OREX : 2.51 (-1.18%)
RDY : 38.30 (-8.09%)
LLY : 83.02 (+1.44%)
AMAG : 19.45 (-2.26%)
VRX : 17.13 (-3.60%)
AMGN : 172.15 (-2.13%)
JUNO : 28.66 (-5.26%)
Edison Issues Outlook on Orexigen Therapeutics (OREX)

LONDON, UK / ACCESSWIRE / June 16, 2017 / Orexigen's (NASDAQ: OREX) consumer-focused re-launch of Contrave continues to be successful with a 39% increase in prescriptions in the United States in Q1-17...

OREX : 2.51 (-1.18%)
Orexigen (OREX) Down 9.4% Since Earnings Report: Can It Rebound?

Orexigen (OREX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OREX : 2.51 (-1.18%)
How These Drug Makers Stocks are Faring? -- Depomed, Pernix Therapeutics, United Therapeutics, and Orexigen Therapeutics

On Tuesday, May 30, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Six out of nine sectors ended Tuesday's trading session in bearish territories....

OREX : 2.51 (-1.18%)
PTX : 3.09 (-1.90%)
UTHR : 125.10 (-4.79%)
DEPO : 10.44 (-4.31%)
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio

Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs

OREX : 2.51 (-1.18%)
NVO : 41.49 (-1.19%)
VVUS : 1.14 (-3.78%)
ARNA : 23.33 (-4.27%)
Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth

On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.

OREX : 2.51 (-1.18%)
CATB : 1.27 (+3.25%)
VVUS : 1.14 (-3.78%)
EPZM : 12.35 (+0.41%)
Orexigen Announces Activities at European Congress on Obesity 2017

Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the company will present two oral presentations on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba®...

OREX : 2.51 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III...

See More

Support & Resistance

2nd Resistance Point 2.66
1st Resistance Point 2.59
Last Price 2.51
1st Support Level 2.45
2nd Support Level 2.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.